4 recruiting, 3 active not recruiting, 3 not yet recruiting. 5 Phase 3, 3 Phase 1, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Active not recruiting 3, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 3 | Recruiting 3 |
| Phase 2 | 1 | Recruiting 1 |
| Phase 4 | 1 | Not yet recruiting 1 |
Follow Thyroid Eye Disease (TED): new trials by email Literature Review of Thyroid Eye Disease (TED) trials Research Report on Thyroid Eye Disease (TED)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-Label Extension Study of MHB018A in Patients With Thyroid Eye Disease MHB018A injection - Thyroid Eye Disease (TED) | Phase 3 | Not yet recruiting | Minghui Pharmaceutical (Hangzhou) Ltd | 219 | 2027-07-01 | 2026-06-04 |
| Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease ETHY-001, Placebo - Thyroid Eye Disease (TED), Graves' Disease | Phase 1 | Recruiting | Ethyreal Bio, Inc. | 72 | 2026-07-06 | 2026-10-26 |
| Prospective Observational Study of Smartphone-Based AI Self-Monitoring During Non-Surgical Treatment for Thyroid Eye Disease (THYROSCOPE) Smartphone-based AI self-monitoring application (Glandy CAS/EXO/LID) - Thyroid Eye Disease (TED), Graves Ophthalmopathy | Not yet recruiting | THYROSCOPE INC. | 200 | 2026-07-01 | 2026-06-03 | |
| A Study of VV-14305 for the Treatment of Thyroid Eye Disease VV-14305, Sham (No Treatment) - Thyroid Eye Disease (TED) | Phase 1 / Phase 2 | Recruiting | Kriya Therapeutics, Inc. | 135 | 2026-05-01 | 2026-08-27 |
| MHB018A Treatment in Patients With Chronic Thyroid Eye Disease MHB018A injection, MHB018A injection Placebo - Thyroid Eye Disease (TED) | Phase 3 | Active not recruiting | Minghui Pharmaceutical (Hangzhou) Ltd | 150 | 2026-03-17 | 2026-09-24 |
| Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease MHB018A injection - Thyroid Eye Disease (TED) | Phase 3 | Recruiting | Minghui Pharmaceutical (Hangzhou) Ltd | 258 | 2026-01-09 | 2026-03-30 |
| Comparison of the Efficacy and Safety of 4 vs. 8 Treatments With Tepezza (Teprotumumab) for Thyroid Eye Disease Teprotumumab Injection [Tepezza] - Thyroid Eye Disease, Thyroid Eye Disease, TED | Phase 4 | Not yet recruiting | Sheba Medical Center | 40 | 2026-01-01 | 2025-12-30 |
| A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease ZL-1109 (VRDN-003), Placebo - Thyroid Eye Disease (TED) | Phase 3 | Active not recruiting | Zai Lab (Shanghai) Co., Ltd. | 108 | 2025-12-05 | 2026-09-09 |
| A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) VRDN-003, Placebo - Thyroid Eye Disease (TED) | Phase 3 | Active not recruiting | Viridian Therapeutics, Inc. | 320 | 2025-02-03 | 2026-05-22 |
| A Study of GenSci098 in Subjects With Active Thyroid Eye Disease GenSci098, GenSci098 Placebo - Safety, Tolerability | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 76 | 2024-09-24 | 2026-02-11 |
Graves Ophthalmopathy (10) · Autoimmune Diseases (1) · Endocrine System Diseases (1) · Exophthalmos (1) · Eye Diseases (1) · Eye Diseases, Hereditary (1) · Goiter (1) · Graves Disease (1) · Hyperthyroidism (1) · Immune System Diseases (1) · Orbital Diseases (1) · Thyroid Diseases (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10) · Genetic Diseases, Inborn (10) · Autoimmune Diseases (9) · Endocrine System Diseases (9) · Exophthalmos (9) · Eye Diseases (9) · Eye Diseases, Hereditary (9) · Goiter (9) · Graves Disease (9) · Hyperthyroidism (9) · Immune System Diseases (9) · Orbital Diseases (9) · Thyroid Diseases (9)
salicylhydroxamic acid (1) · teprotumumab (1)
Minghui Pharmaceutical (Hangzhou) Ltd (3) · Changchun GeneScience Pharmaceutical Co., Ltd. (1) · Ethyreal Bio, Inc. (1) · Kriya Therapeutics, Inc. (1) · Sheba Medical Center (1) · THYROSCOPE INC. (1) · Viridian Therapeutics, Inc. (1) · Zai Lab (Shanghai) Co., Ltd. (1)
China (4) · United States (4) · France (1) · Germany (1) · New Zealand (1) · Poland (1) · Spain (1) · Turkey (Türkiye) (1) · United Kingdom (1)